Stopped: Due to recruitment difficulties, the number of subjects included (n=35) was lower than expected (n=60).
This study is exploratory, non-comparative and open-label, conducted in France. It aims to provide insights into the effectiveness and safety of RV3895A - RY1774, potentially benefiting participants by improving scar appearance and quality of life.The aim of this study is to evaluate the efficacy of the cosmetic product RV3895A - RY1774 on re-epidermised scars of the face and body following burns and surgical stitches in adults, adolescents and children over a 6-month follow-up period. Patients are divided into 2 groups: * Group 1: adults with: * Subgroup 1A: adults with post-burn scar(s) * Subgroup 1C: adults with post-surgical scar(s) requiring stitches to be inserted and removed if applicable (in the case of non-absorbable stitches). * Group 2: children and/or adolescents including children aged 2 to 7 years inclusive with: * Subgroup 2A: children/adolescents with post-burn scar(s) The study consists of 4 visits: Visit 1: Inclusion (Day 1), Visit 2: Intermediate visit (Day 22), Visit 3: Intermediate visit (Day 85), Visit 4: End-of-study visit (planned or anticipated) (Day 169 )
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Physical aspect of scar(s) compared to normal skin by the investigator
Timeframe: Day 1, Day 22, Day 85, and Day 169
Physical and functional aspect of scar(s) by the subject
Timeframe: Day 1, Day 22, Day 85, and Day 169, and monthly at home between Visit 2 and Visit4
Soothing effect
Timeframe: at Day 1 (before and after product application), Day 22, Day 85, and Day 169, and monthly at home between Visit 2 and Visit 4.
Inflammatory aspect of scar
Timeframe: at Day 1, Day 22, Day 85, and Day 169
Evolution of scar aspect compared to Day 1
Timeframe: at Day 22, Day 85, and Day 169
Overall satisfaction with Test product (Investigator's assessment)
Timeframe: at Day 22, Day 85, and Day 169
Overall satisfaction with Test product (Subject/Parent/Guardian assessment)
Timeframe: at Day 22, Day 85, and Day 169
Erythema quantification
Timeframe: at Day 1, Day 22, Day 85, and Day 169
Dermatology Life Quality Index (DLQI)
Timeframe: at Day 1, Day 22, Day 85, and Day 169 and monthly at home between Visit 2 and Visit 4
Specific impact of burns on quality of life
Timeframe: at Day 1, Day 22, Day 85, and Day 169
Visual aspect of the scar through illustrative photographs
Timeframe: at Day 1, Day 22, Day 85, and Day 169.
The quantity of product used calculated by weighing the tubes
Timeframe: Between Day 1 and Day 169
Subjective cosmetic acceptability of the product
Timeframe: at Day 22, Day 85, and Day 169
Recording of adverse events
Timeframe: at Day 1 (first application of the product on site), Day 22, Day 85, and Day 169
Overall tolerance assessed by the investigator
Timeframe: at Day 22, Day 85, and Day 169
Compliance
Timeframe: Duration of the study, from Day 1 to Day 169